Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05376501 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the Effect of Astaxanthin in Healthy Participants
A NA study, sponsored by LycoRed.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT05376501: Completed NA study, sponsored by LycoRed.
NCT05376501 is a NA study that has completed, run by LycoRed. The registered enrollment target is 60 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05376501, a NA study, has completed, sponsored by LycoRed.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
Astaxanthin is recognized as a bioactive compound with potential benefits for human health. This study aims to evaluate a specific nutritional supplement impact on markers of oxidative stress, inflammation, lipid levels, blood flow, visual skin markers, measures of longevity, mood and skin condition.
Primary Outcome
Change from baseline in plasma/serum total antioxidant capacity
Interventions
- DIETARY_SUPPLEMENT Astaxanthin
- OTHER Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-06-08 |
| Est. Completion | 2022-10-15 |
| Phase | NA |
What the finished NCT05376501 record still lists
NCT05376501 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Astaxanthin is the first listed.
NCT05376501 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05376501 about?
NCT05376501 is a clinical study titled "A Study to Evaluate the Effect of Astaxanthin in Healthy Participants". Astaxanthin is recognized as a bioactive compound with potential benefits for human health. This study aims to evaluate a specific nutritional supplement impact on markers of oxidative stress, inflammation, lipid levels, blood flow, visual skin markers, measures of longevity, mood and skin condition...
What is the current status of trial NCT05376501?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2022-06-08. Estimated completion is 2022-10-15.
What interventions are being tested in trial NCT05376501?
The interventions under investigation include: Astaxanthin (DIETARY_SUPPLEMENT), Placebo (OTHER).
Who is sponsoring clinical trial NCT05376501?
This trial is sponsored by LycoRed, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05376501's enrollment target sits among peer trials
60 1164th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI